GlassScriptPhysician profile
Matthew Bessom
NPI 1821251166
$10,993.83
in general payments reported to CMS, 2019-2025
47 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,960 · 2020: $483 · 2021: $1,959 · 2022: $2,095 · 2023: $1,456 · 2024: $1,588 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,497.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,915.89 | 2019-2025 | |
| Abbvie INC. | $1,155.08 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $989.64 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $902.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $822.69 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $725.23 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $476.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $389.44 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $348.78 | 2020-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $336.46 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.63 | 2019-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $298.80 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $289.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $262.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $238.35 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $162.62 | 2021-2025 | Freestyle Libre 3, Eterna |
| Takeda Pharmaceuticals U.S.A., INC. | $162.38 | 2019-2022 | |
| Daiichi Sankyo INC. | $144.31 | 2022-2024 | Injectafer |
| Heartflow, INC. | $114.71 | 2025 | |
| Eisai INC. | $85.58 | 2020-2021 | |
| Astellas Pharma US INC | $83.38 | 2019-2022 | |
| Esperion Therapeutics, INC. | $74.71 | 2021-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $73.12 | 2020-2021 | |
| Allergan, INC. | $56.99 | 2019-2020 | |
| Genentech USA, INC. | $50.47 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $40.28 | 2023-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $40.05 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $39.41 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $38.00 | 2024-2025 | Voquezna |
| Alkermes, INC. | $34.57 | 2025 | Vivitrol |
| Edwards Lifesciences Corporation | $33.72 | 2024 | |
| Nevro Corp. | $30.37 | 2022-2023 | Senza |
| Ars Pharmaceuticals Operations, INC. | $29.53 | 2025 | Neffy |
| Dexcom, INC. | $24.71 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $24.16 | 2023 | Inspire |
| Antares Pharma, INC. | $24.11 | 2023 | Xyosted, Tlando, Nocdurna |
| Resmed Corp | $22.50 | 2019 | |
| Philips North America LLC | $19.35 | 2024 | (Ck7) Extended Holter |
| Axsome Therapeutics, INC. | $17.40 | 2025 | Auvelity |
| Inogen, INC. | $17.16 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.23 | 2022 | |
| Medtronic, INC. | $14.78 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.44 | 2021 | |
| Boston Scientific Corporation | $14.29 | 2024 | |
| Exact Sciences Corporation | $14.10 | 2025 | Cologuard Collection Kit |
| Halozyme INC | $13.45 | 2023 | |
| Horizon Therapeutics Plc | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bessom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.